Evidence for the vitamin D hypothesis: The NHANES III extended mortality follow-up

doi:10.1016/j.atherosclerosis.2016.04.007

Atherosclerosis

Volume 255, December 2016, Pages 96-101

https://doi.org/10.1016/j.atherosclerosis.2016.04.007 Get rights and content

Abstract

Background and aims

Emerging evidence suggests that low levels of vitamin D may be an important risk factor for multiple chronic diseases and mortality, but the evidence is mixed. Vitamin D levels are associated with sun exposure, diet, and metabolic status. One potential explanation for the lack of consistent findings amongst various studies is that low vitamin levels may be associated with poor diets or other risk factors that we were not adequately controlled for in different analyses.

Methods

Prospective analysis of adults over the age of 35 in NHANES III data (1988–1994) with 20 year mortality follow-up. Sequential Cox proportional hazard models quartiles of 25OH vitamin D adjusted for age, season, geography, sociodemographic (SD), CVD risk factors (CVD) and nutritional factors (NF) were performed.

Results

Gender, race, diabetes, anti-hypertensive meds, income, taking vitamin D supplements, physical activity, alcohol consumption, region, body mass index, blood pressure, creatinine, albumin, CRP, thyroxine, iron, RBC folate, vitamin A, E, alpha-carotene, and lycopene were all associated with different quartiles of vitamin D and as well as CHD and all-cause mortality and thus are important potential confounders of this relationship. Adjusting for the confounding factors, higher levels of vitamin D demonstrate an inverse relationship with all-cause mortality, but only the top quartile of vitamin D shows an inverse relationship with CHD mortality.

Conclusions

The highest quartile compared to the lowest quartile of 25OH vitamin D levels is inversely associated with CHD and all-cause mortality adjusting for multiple confounders. Whether supplementation of individuals with low vitamin D will result in similar benefits will require a randomized clinical trial.

Introduction

Vitamin D is well known for its role in regulating calcium and phosphorus metabolism and therefore its role in bone health and renal disease is well established [1], [2]. Emerging evidence suggests that low levels of vitamin D might be an important risk factor for multiple chronic diseases and contribute to the development of cardiovascular, cancer and mortality, but the evidence is mixed. A previous analysis of the Third National Health and Nutrition Examination Survey (NHANES III) with mortality follow-up study through 2000 showed a modest association (RR = 1.26, 95% CI 1.08–1.46) with all-cause mortality and evidence for a threshold effect at moderate levels of 25(OH) vitamin D [3]. In addition, Martins D et al. reported that low levels of 25(OH) D were associated with multiple cardiovascular risk factors in the NHANES III population [4]. Other studies showed that low levels of 25(OH) D are associated independently with diabetes mellitus [5], congestive heart failure [6], hypertension [7], and cancer [8].

Vitamin D levels depend on sun exposure, diet, and metabolic status of an individual. One potential explanation for the lack of consistent findings among various studies is that low vitamin D levels may be associated with poor diets or other risk factors that were not adequately controlled for in analyses. NHANES III allows for dietary and serum assessments of multiple potentially confounding CHD risk factors and dietary variables to be assessed which have not been utilized in previous analyses.

We hypothesized that low serum 25(OH) vitamin D levels are associated with all-cause mortality independent of sociodemographic factors, cardiovascular risk factors and as well as markers of overall diet; among adults in the United States.

Section snippets

Study participants

We conducted a prospective analysis of adults who participated in the Third National Health and Nutrition Examination Survey (NHANES III) (1988–1994) [9]. NHANES III [10] is a nationwide probability sample of 33,994 civilian non-institutionalized person's age 2 months and over. The study was carried out by the National Center for Health Statistics of the Centers for Disease Control and Prevention. A stratified multistage sampling design was used to create a nationally representative sample of

Results

Examining vitamin D levels by quartiles, there is an inverse relationship between of vitamin D levels and male sex, African American race, DM, hypertension, current smoking, income, not taking vitamin D supplement, lower levels of physical activity, lower frequency of alcohol consumption, higher BMI, higher systolic BP, lower albumin, higher CRP, lower serum transferrin saturation, lower serum retinyl ester, higher serum lipoprotein(a), lower total serum carotenoids, serum alpha carotene,

Discussion

Our study confirms and extends the work of Melamed et al. who demonstrated that low vitamin D was a risk factor for total mortality adjusting for CVD risk factors and markers of a healthy lifestyle [3]. They did not adjust for other dietary variables that were associated with 25OH vitamin D levels that might have been markers of poor or healthier diets. Compared to other NHANES analyses [3], [19], [20], our analysis showed that even when adjusting for dietary effects, the risk of low vitamin D

Conflict of interest

The authors declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

References (26)

M. Chonchol et al.
25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey
Kidney Int.
(Jan;2007)
A.C. Looker et al.
Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III
Bone
(2002 May)
C.E. Woteki et al.
Selection of nutrition status indicators for field surveys: the NHANES III design
J. Nutr.
(1990 Nov)
M. Visser et al.
Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission
Am. J. Clin. Nutr.
(2006 Sep)
N.C. Grandi et al.
Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies
Prev. Med.
(2010 Sep-Oct)
J.E. Manson et al.
The vitamin D and omegA-3 Trial (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease
Contemp. Clin. Trials
(2012)
M.J. Bolland et al.
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
BMJ
(2010 Jul 29)
IOM (Institute of Medicine)
Dietary Reference Intakes for Calcium and Vitamin D. Washington DC
(2011)
M.L. Melamed et al.
25-hydroxyvitamin D levels and the risk of mortality in the general population
Arch. Intern Med.
(2008 August 11)
D. Martins et al.
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxy vitamin d in the United States: data from the third national health and nutrition examination Survey
Arch. Intern Med.
(Jun 11 2007)

A. Zittermann et al.

Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?

J. Am. Coll. Cardiol.

(Jan 1;2003)

J.P. Forman et al.

Plasma 25-Hydroxyvitamin D levels and risk of incident hypertension

Hypertension

(2007 May)

E. Giovannucci et al.

Prospective study of predictors of vitamin D status and cancer incidence and mortality in men

J. Natl. Cancer Inst.

(Apr 5;2006)

Cited by (31)

Polymorphisms in the vitamin D system and mortality – The Tromsø study
2019, Journal of Steroid Biochemistry and Molecular Biology
Citation Excerpt :
However, no significant relations between mortality and VDR and MEGALIN SNPs, or a genetic score based on SNPs involved in transportation and degradation of 25(OH)D, were found. As for the relation between serum 25(OH)D level and mortality, this is well established in numerous studies [24,32–34], and was in our study not affected by adjusting for sex or age, nor for the cardiovascular risk factor smoking, BMI, systolic blood pressure, or serum lipids. Due to the high risk of reverse causality a low serum 25(OH)D may be the result as well as the cause of disease.
Vitamin D deficiency is associated with diabetes, cancer, immunological and cardiovascular diseases as well as increased mortality. It has, however, been difficult to show a causal relation in randomized, controlled trials. Mendelian randomization studies provide another option for testing causality, and results indicate relations between the serum 25-hydroxyvitamin D (25(OH)D) level and some diseases, including mortality. We have from the Tromsø Study in 2012 published non-significant relations been vitamin D related single nucleotide polymorphisms (SNPs) and mortality, but have since then genotyped additional subjects, the observation time is longer and new SNPs have been included. For the present study genotyping was performed for SNPs in the NADSYN1, CYP2R1, GC and CYP24A1, VDR, CUBILIN and MEGALIN genes in 11 897 subjects who participated in the fourth survey of the Tromsø Study in 1994–1995. Serum 25(OH)D levels were measured in 6733 of these subjects. Genetic scores based on SNPs related to the serum 25(OH)D level (NADSYN1 and CYP2R1 SNPs (synthesis score) and GC and CYP24A1 SNPs (metabolism score)) and serum 25(OH)D percentile groups were created. Mortality data was updated till end of March 2017 and survival analysed with Cox regression adjusted for sex and age. During the observation period 5491 subjects died. The 25(OH)D synthesis (but not the metabolism) genetic score and the serum 25(OH)D percentile groups were (without Bonferroni correction) significantly related to mortality in favour of high serum 25(OH)D. None of the SNPs in the VDR or MEGALIN genes were related to mortality. However, for the rs12766939 in the CUBILIN gene with the major homozygote as reference, the hazard ratio for mortality for the minor homozygote genotype was 1.17 (1.06–1.29), P < 0.002. This should be viewed with caution, as rs12766939 was not in Hardy-Weinberg equilibrium. In conclusion, our study confirms a probable causal but weak relation between serum 25(OH)D level and mortality. The relation between rs12766939 and mortality needs confirmation in more homogenous cohorts.
Interleukin 17A in atherosclerosis – Regulation and pathophysiologic effector function
2019, Cytokine
Citation Excerpt :
Vitamin D suppresses TH17 differentiation [45,47,48]. Vitamin D levels negatively correlate with cardiovascular event rate [49–51]. Lipid metabolism, especially intracellular cholesterol, centrally modulates TH17 pathogenicity [52,53].
This review summarizes the current data on the interleukin (IL)-17A pathway in experimental atherosclerosis and clinical data.
IL-17A is a prominent cytokine for early T cell response produced by both innate and adaptive leukocytes. In atherosclerosis, increased total IL-17A levels and expression in CD4⁺ T helper and γδ T cells have been demonstrated. Cytokines including IL-6 and TGFβ that increase IL-17A expression are elevated. Many other factors such as lipids, glucose and sodium chloride concentrations as well as vitamins and arylhydrocarbon receptor agonists that promote IL-17A expression are closely associated with cardiovascular risk in the human population. In acute inflammation models, IL-17A mediates innate leukocyte recruitment of both neutrophils and monocytes. In atherosclerosis, IL-17A increased aortic macrophage and T cell infiltration in most models. Secondary recruitment effects via the endothelium and according to recent data also pericytes have been demonstrated. IL-17 receptor A is highly expressed on monocytes and direct effects have been reported as well. Beyond leukocyte accumulation, IL-17A may affect other factors of plaque formation such as endothelial function, and according to some reports, fibrous cap formation and vascular relaxation with an increase in blood pressure. Anti-IL-17A agents are now available for clinical use. Cardiovascular side effect profiles are benign at this point.
IL-17A appears to be a differential regulator of atherosclerosis and its effects in mouse models suggest that its modulation may have contradictory effects on plaque size and possibly stability in different patient populations.
Serum 25-Hydroxyvitamin D Values and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort Study
2018, Mayo Clinic Proceedings
Citation Excerpt :
Most previous studies involved predominantly white populations of European descent with minimal inclusion of other races/ethnicities. Of studies that adjusted for race/ethnicity,8,11,26,31-34 an interaction between the effect of race/ethnicity and 25(OH)D on all-cause mortality was not described. All-cause mortality data from the NHANES-III included an oversampling of participants whose race/ethnicity was other than white, and in a subgroup analysis, investigators reported a nonsignificant interaction by race/ethnicity.9
To determine the relationship between 25-hydroxyvitamin D (25[OH]D) values and all-cause and cause-specific mortality.
We identified all serum 25(OH)D measurements in adults residing in Olmsted County, Minnesota, between January 1, 2005, and December 31, 2011, through the Rochester Epidemiology Project. All-cause mortality was the primary outcome. Patients were followed up until their last clinical visit as an Olmsted County resident, December 31, 2014, or death. Multivariate analyses were adjusted for age, sex, race/ethnicity, month of measurement, and Charlson comorbidity index score.
A total of 11,022 individuals had a 25(OH)D measurement between January 1, 2005, and December 31, 2011, with a mean ± SD value of 30.0±12.9 ng/mL. Mean age was 54.3±17.2 years, and most were female (77.1%) and white (87.6%). There were 723 deaths after a median follow-up of 4.8 years (interquartile range, 3.4-6.2 years). Unadjusted all-cause mortality hazard ratios (HRs) and 95% CIs for 25(OH)D values of less than 12, 12 to 19, and more than 50 ng/mL were 2.6 (95% CI, 2.0-3.2), 1.3 (95% CI, 1.0-1.6), and 1.0 (95% CI, 0.72-1.5), respectively, compared with the reference value of 20 to 50 ng/mL. In a multivariate model, the interaction between the effect of 25(OH)D and race/ethnicity on mortality was significant (P<.001). In white patients, adjusted HRs for 25(OH)D values of less than 12, 12 to 19, 20 to 50, and greater than 50 ng/mL were 2.5 (95% CI, 2.2-2.9), 1.4 (95% CI, 1.2-1.6), 1.0 (referent), and 1.0 (95% CI, 0.81-1.3), respectively. In patients of other race/ethnicity, adjusted HRs were 1.9 (95% CI, 1.5-2.3), 1.7 (95% CI, 1.1-2.6), 1.5 (95% CI, 1.0-2.0), and 2.1 (95% CI, 0.77-5.5).
White patients with 25(OH)D values of less than 20 ng/mL had greater all-cause mortality than those with values of 20 to 50 ng/mL, and white patients had greater mortality associated with low 25(OH)D values than patients of other race/ethnicity. Values of 25(OH)D greater than 50 ng/mL were not associated with all-cause mortality.
The IOM-Endocrine Society Controversy on Recommended Vitamin D Targets: In Support of the Endocrine Society Position
2018, Vitamin D: Fourth Edition
There is still controversy about the amount of vitamin D adults need for musculoskeletal health. The Endocrine Society, which made its recommendations for the treatment and prevention of vitamin D deficiency, concluded that to guarantee bone health without any evidence for vitamin D deficiency osteomalacia, a blood level of 25(OH)D of at least 75 nmol/L (30 ng/mL) was required for adults. As a result the Endocrine Society recommended that for adults 1500–2000 IU/day was required for musculoskeletal health and noted that obese adults require 2–3 times more vitamin D to sustain a blood level of 25(OH)D of at least 75 nmol/L. The more conservative recommendation from the Institutes of Medicine (IOM) is the recommended dietary allowance (RDA) for vitamin D, 600 IU/day (15 μg/day), which the IOM claims sustains 97.5% of the population with serum 25(OH)D above the threshold of 50 nmol/L (20 ng/mL). We show how the IOM made incorrect analyses of the evidence it cited, thereby severely underestimating the serum 25(OH)D threshold. Furthermore, to calculate the intake of vitamin D needed to deliver the threshold serum level, the IOM used group average serum 25(OH)D responses to establish the vitamin D RDA. Because half of a population needs more than the average, the 600 IU/day RDA for vitamin D underestimates the intake needed to assure the threshold for 97.5% of the population. For people who are sun-deprived or with darker skin at temperate latitudes, the 600 IU/day RDA cannot assure the threshold serum level. The IOM specified 4000 IU/day for most children and adults to the safe, upper level for vitamin D, whereas the Endocrine Society specified 4000 IU/day for most children and 10,000 IU/day for adults. Although the IOM did not base its 50 nmol/L (20 ng/mL) threshold for serum 25(OH)D for musculoskeletal health on randomized clinical trials (RCTs), advocates of the IOM position now reject the normal criteria for evidence-based decisions and demand that RCTs are needed for acceptance of any extraskeletal health relationship. We contend that it is unrealistic to ever expect that RCTs can be conducted for vitamin D in the long-term primary prevention of disease events in a healthy adult population under age 50 years. The existing prospective, cross-sectional, and clinical trial evidence for mortality and premature delivery in pregnancy is already enough to warrant further increases in recommendations for vitamin D supplementation.
Role of Vitamin D in Cardiovascular Diseases
2017, Endocrinology and Metabolism Clinics of North America
Citation Excerpt :
The low levels of vitamin D in these studies may be due to different confounding factors, such as environment, age, sex, socioeconomic status, and nutritional status. Daraghmeh and colleagues24 conducted a National Health and Nutrition Examination Survey III follow-up study on extended mortality and found that low vitamin D levels are inversely associated with CAD and all-cause mortality adjusting for multiple confounders. In animals, Assalin and colleagues25 studied the effect of vitamin D deficiency on cardiac metabolism, morphology, and function using male weanling Wistar rats.
Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study
2023, Nutrients

View all citing articles on Scopus

View full text

Evidence for the vitamin D hypothesis: The NHANES III extended mortality follow-up

Abstract

Background and aims

Methods

Results

Conclusions

Introduction

Section snippets

Study participants

Results

Discussion

Conflict of interest

Kidney Int.

Bone

J. Nutr.

Am. J. Clin. Nutr.

Prev. Med.

Contemp. Clin. Trials

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

BMJ

Dietary Reference Intakes for Calcium and Vitamin D. Washington DC

25-hydroxyvitamin D levels and the risk of mortality in the general population

Arch. Intern Med.

Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxy vitamin d in the United States: data from the third national health and nutrition examination Survey

Arch. Intern Med.

Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?

J. Am. Coll. Cardiol.

Plasma 25-Hydroxyvitamin D levels and risk of incident hypertension

Hypertension

Prospective study of predictors of vitamin D status and cancer incidence and mortality in men

J. Natl. Cancer Inst.